REG - Polarean Imaging PLC - Appointment of Vice President of Sales

Polarean ImagingAnnouncement

03/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240903:nRSC5963Ca&default-theme=true

RNS Number : 5963C  Polarean Imaging PLC  03 September 2024

3 September
2024

 

Polarean Imaging plc

("Polarean" or the "Company")

 

Appointment of Alan Huang, Ph.D., as Vice President of Sales

Experienced business leader with extensive commercial experience in Magnetic
Resonance Imaging

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in
advanced Magnetic Resonance Imaging ("MRI") of lung function, is pleased to
announce the appointment of Alan Huang, Ph.D. as Vice President of Sales.

 

Dr. Huang brings extensive knowledge and 15 years of experience in the medical
device industry, with specific expertise in MRI and MRI-based technologies. He
is skilled in executing strategic plans and driving revenue growth of novel
technologies. Dr. Huang joins Polarean after nearly 12 years at Philips
Healthcare, where he held various roles, most recently as North American
Business Leader for the MRI business unit. In this role, he was directly
responsible for P&L management and directing the sales and marketing
teams. Dr. Huang also developed strategic plans for market growth, supported
the reorganisation of the commercial organisation to sharpen its focus on key
markets, and hired channel partners to assist in the management of the
business in non-core markets.

 

As VP of Sales, Dr. Huang will be responsible for driving Polarean's sales
strategy and leading the Company's expanding sales team as it accelerates the
market adoption of its pulmonary functional Xenon MRI platform technology
(https://xenoview.net/) . He will focus on expanding the technology's
footprint in academic medical centers and driving utilization across the
growing install base, enabling improved characterisation and management of
chronic lung disease for patients and their clinicians.

 

Dr. Huang holds a Ph.D. in Biomedical Engineering from Johns Hopkins
University School of Medicine in Baltimore, MD, and a double Bachelor of
Science degree in Neurobiology and Electrical and Computer Engineering from
the University of Texas at Austin.

 

Christopher von Jako, Ph.D., CEO of Polarean, said: "I am extremely delighted
to welcome Alan to the Polarean team as our VP of Sales. Having gotten to know
him over the past year during our collaboration with Philips, I am confident
that he brings a wealth of experience and insights that will greatly
complement our current commercial team. This appointment comes at an ideal
time following our recent financing, as we aim to expand our sales
infrastructure with best-in-class talent to accelerate the adoption of our
Xenon MRI technology. Alan's extensive experience at Philips, where he
successfully grew their MR business and built strong relationships with a
large number of academic medical centres and clinicians across the US, makes
him a tremendous asset to Polarean."

 

Alan Huang, Ph.D., VP of Sales at Polarean, said: "In my previous roles in
diagnostic MRI and Radiation Therapy solutions, I recognised the potential of
Polarean's Xenon MRI technology to significantly improve the characterisation
and management of chronic lung diseases. Through the Philips partnership with
Polarean and numerous conversations with customers, I became more aware of the
significant unmet clinical need and was impressed by the Company's innovative
approach. I am excited to join Polarean and work with the team to expand the
reach of Xenon MRI platform technology across the pulmonary clinical
community."

 

Click here
(https://www.voxmarkets.co.uk/articles/polarean-interview-with-ceo-christopher-von-jako-6cd4019)
for an interview with Christopher von Jako on the appointments of Alan Huang,
Ph.D., VP of Sales, and Chase Hall, M.D., Chief Medical Advisor.

 

Enquiries:

 

 Polarean Imaging plc                                        www.polarean.com / www.polarean-ir.com (http://www.polarean-ir.com)
 Christopher von Jako, Ph.D., Chief Executive Officer        Via Walbrook PR
 Charles Osborne, Chief Financial Officer

 Stifel (NOMAD and Sole Corporate Broker)                                             +44 (0)20 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Walbrook PR         Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy / Phillip Marriage          Mob: +44 (0)7876 741 001 / +44 (0)7867 984 082

 

About Polarean

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW™, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform. For the latest news and information about Polarean,
please visit www.polarean.com (http://www.polarean.com/) .

 

XENOVIEW IMPORTANT SAFETY INFORMATION

 

Indication

XENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized
contrast agent indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients aged 12 years
and older.

 

Limitations of Use

XENOVIEW has not been evaluated for use with lung perfusion imaging.

 

CONTRAINDICATIONS

None.

 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause degradation of
image quality. For patients on supplemental oxygen, withhold oxygen inhalation
for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.

 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may
cause transient hypoxemia in susceptible patients. Monitor all patients for
oxygen desaturation and symptoms of hypoxemia and treat as clinically
indicated.

 

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient)
in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse
Reactions in Pediatric and Adolescent Patients: In published literature in
pediatric patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness, tingling,
dizziness, and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient increase in
heart rate was reported following hyperpolarized xenon Xe 129 administration.
XENOVIEW is not approved for use in pediatric patients less than 12 years of
age.

 

Please see full prescribing information at www.XENOVIEW.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUPUAUBUPCGQP